Piramal Pharma Limited (PPLPHARMA) — Capital Reinvestment Ratio
Piramal Pharma Limited (PPLPHARMA) has a Capital Reinvestment Ratio of 0.49x as of September 2025, meaning it reinvests 0% of its operating cash flow (Rs8.90 Billion) in capital expenditures (Rs4.33 Billion). Check PPLPHARMA tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Piramal Pharma Limited Capital Reinvestment Ratio (2021–2026)
This chart tracks Piramal Pharma Limited's Capital Reinvestment Ratio across 6 annual periods. For the full cash flow conversion analysis, see PPLPHARMA cash flow metrics.
Annual Capital Reinvestment Ratio for Piramal Pharma Limited (2021–2026)
Year-by-year Capital Reinvestment Ratio for Piramal Pharma Limited from 2021 to 2026. See Piramal Pharma Limited free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (INR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2026 | 0.64x | Rs14.00 Billion | Rs8.90 Billion | ▼ -14.6% |
| 2025 | 0.74x | Rs8.92 Billion | Rs6.64 Billion | ▲ +5.0% |
| 2024 | 0.71x | Rs10.05 Billion | Rs7.12 Billion | ▼ -64.4% |
| 2023 | 1.99x | Rs4.84 Billion | Rs9.65 Billion | ▲ +153.8% |
| 2022 | 0.79x | Rs2.55 Billion | Rs2.01 Billion | ▼ -53.1% |
| 2021 | 1.67x | Rs347.20 Million | Rs581.10 Million | — |